A child is diagnosed with absence seizures, and the prescriber orders ethosuximide (Zarontin). When teaching the child's parents about dosage adjustments for this drug, the nurse will stress the importance of:

A. Ethosuximide (Zarontin) is the first-line therapy for absence seizures in children. Its dosage is typically titrated based on the clinical response, which is measured by the frequency and severity of seizures. Parents should be instructed to maintain a daily seizure diary, noting the time of day, duration, and characteristics of each seizure, as well as potential triggers. This data is crucial because serum drug levels do not always correlate with seizure control, and adjustments must be guided by actual seizure activity. Recording seizure patterns allows the prescriber to determine whether the current dose is effective or needs to be increased. B. Dizziness and drowsiness are known adverse effects of ethosuximide. While parents should report these symptoms to ensure safety, they are not the primary indicator for adjusting the drug dose unless they become severe. Dose changes are generally guided by seizure frequency rather than side effects alone. C. Routine serum drug level monitoring is usually not necessary for ethosuximide. It may only be done if there are concerns about toxicity, adherence, or unusual metabolism. Clinical observation is the mainstay for dose titration. D. Although educating parents about absence seizures, treatment rationale, and safety measures is essential for adherence and overall management, it does not replace the need to track seizures when adjusting the dose. Education supports care but is not the primary determinant for titration.